Evidence map›Paper›PMID 22205602›Full record

ArticleInvestigative ophthalmology & visual science2012

Spliceosome protein (SRp) regulation of glucocorticoid receptor isoforms and glucocorticoid response in human trabecular meshwork cells.

Ankur Jain, Robert J Wordinger, Thomas Yorio, Abbot F Clark

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Investigative ophthalmology & visual science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Glucocorticoid-Induced Ocular Hypertension and Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2024
    Review
  9. Review
  10. Article
  11. iPSCs-Based Therapy for Trabecular Meshwork.Handbook of experimental pharmacology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Glucocorticoid Receptor β (GRβ): Beyond Its Dominant-Negative Function.International journal of molecular sciences · 2021
    Review
  16. Article
  17. Article
  18. The many faces of the trabecular meshwork cell.Experimental eye research · 2017
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ankur JainDepartment of Cell Biology and Anatomy, University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas 76107, USA. anjain@live.unthsc.edu
Robert J Wordinger
Thomas Yorio
Abbot F Clark
Institute of Cell Biology and Neurobiology · IT

Funding

Glucocorticoids, Ocular Hypertension, and GlaucomaR01EY016242 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI CLARK, ABBOT FREDERICK · 2005 to 2018
$4.1M
NEI NIH HHS R01 EY016242
6 · The paper itself

Abstract

purposeGlaucoma is a leading cause of visual impairment and blindness, with elevated intraocular pressure (IOP) as a major causative risk factor. Glucocorticoid (GC) therapy causes morphologic and biochemical changes in the trabecular meshwork (TM), an ocular tissue involved in regulating IOP, which can lead to the development of glaucoma in susceptible individuals (steroid responders). Steroid responders comprise 40% of the general population and are at higher risk of developing glaucoma. In addition, a majority of glaucoma patients are steroid responders. Differential distribution of various isoforms of GC receptor (GR) may be responsible for this heterogeneity in the steroid response. The alternatively spliced GRβ isoform acts as dominant negative regulator of classical GRα transcriptional activity. mRNA splicing is mediated by spliceosomes, which include serine-arginine rich proteins (SRps). The purpose of this study was to determine whether specific SRps regulate levels of these isoforms and thereby GC response in TM cells.

methodsQuantitative RT-PCR, Western blot analysis, and immunocytochemistry were used to determine the differential expression of different SRps (SRp20, 30c, and 40) in human normal and glaucomatous TM cell strains. Bioinformatics was used to find putative binding sites for SRp20 and SRp40 on exon 9 of the GR gene. A peptide modulator of splicing (bombesin) and SRp expression vectors were used to modulate SRp levels and determine their effects on GRα/GRβ ratios as well as dexamethasone (DEX) responsiveness via GRE- luciferase reporter activity, fibronectin, and myocilin induction in TM cells.

resultsSRp20, SRp30c, and SRp40 regulate GR splicing and the GC response in TM cells. Modulation of SRp levels altered the GRβ/α ratio that correlated with DEX responsiveness. Bombesin decreased SRp20; increased SRp30c, SRp40 levels, and GRβ/α ratio, and suppressed DEX response in TM cells.

conclusionsRelative levels of SRp20, SRp30c, and SRp40 in TM cells control differential expression of the two alternatively spliced isoforms of the GR and thereby regulate GC responsiveness. Different levels and/or activities of these SRps may account for differential GC sensitivity among the normal and glaucoma populations.

Indexed as

Gene Expression RegulationBlotting, WesternCells, CulturedElectrophoresis, Agar GelEnzyme-Linked Immunosorbent AssayGene FrequencyGlaucomaGlucocorticoidsHumansImmunohistochemistryNuclear ProteinsReal-Time Polymerase Chain ReactionReceptors, GlucocorticoidRNA-Binding ProteinsRNA, MessengerSerine-Arginine Splicing Factorsglucocorticoid receptor alphaglucocorticoid receptor betaGlucocorticoidsNuclear ProteinsReceptors, GlucocorticoidRNA-Binding ProteinsRNA, MessengerSerine-Arginine Splicing FactorsSRSF3 protein, human

Identifiers

PMID22205602
PMCPMC3317424
OpenAlexW2057323820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.